TY - JOUR T1 - Mechanism-Based Inactivation of Cytochrome P450 2A6 by Decursinol Angelate Isolated from <em>Angelica Gigas</em> JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1759 LP - 1765 DO - 10.1124/dmd.107.016584 VL - 35 IS - 10 AU - Hye Hyun Yoo AU - Min Woo Lee AU - Young Choong Kim AU - Chul-Ho Yun AU - Dong-Hyun Kim Y1 - 2007/10/01 UR - http://dmd.aspetjournals.org/content/35/10/1759.abstract N2 - The inhibition of CYP2A6 by decursinol angelate, a pyranocoumarin isolated from Angelica gigas roots, was examined in human liver microsomes and recombinant CYP2A6. Decursinol angelate moderately inhibited coumarin 7-hydroxylation, but a 20-min preincubation with microsomes and NADPH significantly increased its inhibitory effect (IC50; &gt;20 versus 4.4 μM). A similar inhibition pattern was observed in nicotine C oxidation, which is also one of the prototype reactions of CYP2A6. Inactivation by decursinol angelate was selective for CYP2A6 and characterized by KI values of 0.99 and 2.42 μM and the kinact values of 0.136 and 0.053 min-1 in microsomes and recombinant CYP2A6, respectively. This inactivation was not protected or restored by nucleophiles, reactive oxygen scavengers, or extensive dialysis but was inhibited by the addition of a competitive CYP2A6 inhibitor, pilocarpine. Furthermore, incubation of CYP2A6 with decursinol angelate in the presence of NADPH resulted in a loss of the spectral CYP2A6 content. An in vitro metabolism study revealed that CYP2A6 oxidized decursinol angelate to the dihydrodiol metabolite, presumably via an epoxide intermediate that might be responsible for the inactivation of CYP2A6. These results collectively demonstrated that decursinol angelate inactivated CYP2A6 in a mechanism-based mode. The American Society for Pharmacology and Experimental Therapeutics ER -